drugset / Trial / NCT03529136
Clinical Trial of Umbilical Cord Mesenchymal Stem Cell Transfusion in Decompensated Liver Cirrhosis
Phase 2
Unknown
252 enrolled
Shandong Qilu Stem Cells Engineering Co., Ltd.
First Affiliated Hospital of Fujian Medical University · collabJinan Hospital for Infectious Diseases · collabShanghai Public Health Clinical Center · collabThe Second Affiliated Hospital of Chongqing Medical University · collabYantai Hospital for Infectious Diseases · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Decompensated liver cirrhosis is one of the life-threatening complication of chronic liver disease. Liver transplantation currently is the only effective method that can improve the survival of these patients. However, the severe shortage of donor livers, high cost, and potential serious complications have restricted the availability of liver transplantation.Umbilical cord mesenchymal stem cells (UC-MSC) has been generally shown to be safe and effective for liver diseases in some pre-clinical and clinical studies. This study aim to evaluate the safety and efficiency of human umbilical cord mesenchymal stem cell transfusion in patients with decompensated liver cirrhosis, and explore the best protocol of MSC transfusion.
Timeline
- Start
- 2018-06-01
- Primary completion
- 2019-12-31
- Completion
- 2020-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | human umbilical cord mesenchymal stem cells | Cell therapy | 1.5e+06 cells/kg | Other |